

<b>Patient Name</b> SAMPLEREP, CVID	<b>Patient ID</b> SA00057316	<b>Age</b> 46	<b>Gender</b> F	<b>Order #</b> SA00057316
<b>Ordering Phys</b> CLIENT, CLIENT				<b>DOB</b> 06/10/1966
<b>Client Order #</b> SA00057316	<b>Account Information</b>			<b>Report Notes</b>
<b>Collected</b> 05/08/2013 00:00	C7028846-DLMP Rochester SDSC 2 - Client Support Rochester, MN 55901			
<b>Printed</b> 10/03/2013 15:43				

Test	Flag	Results	Unit	Reference Value	Perform Site*
<b>CVID Confirmation Flow Panel</b>					
<b>RECEIVED:</b> 05/09/2013 15:25 <b>REPORTED:</b> 10/03/2013 13:02					
CD19+ TACI+ % of CD19 B cells		12.3	%	>3.4	MCR
CD19+ BAFF-R+ % of CD19 B cells		96.2	%	>90.2	MCR
<b>Interpretation</b>					

Normal expression of BAFF-R. Normal expression of TACI. The presence of normal TACI expression on B cells does not rule out the possibility that a TACI mutation may be present. Only 5% of TACI mutations are associated with a protein defect that can be detected by flow cytometry. Approximately 95% of TACI mutations are associated with functional defects but normal protein expression. Suggest TACI genotyping if clinical evidence for CVID and associated TACI defect may be present (such as absent or low IgA, autoimmune thyroid disease or autoimmune cytopenias, lymphoproliferative disease, family members with IgA deficiency and/or CVID with some of these clinical features). Unable to provide further interpretation without clinical information. Clinical correlation recommended.

Analyte Specific Reagent: This test was developed and its performance characteristics determined by Mayo Clinic. It has not been cleared or approved by the U.S. Food and Drug Administration.

\* Performing Site:

MCR	Mayo Clinic Laboratories - Rochester Main Campus 200 First St SW Rochester, MN 55905	Lab Director:
-----	---	---------------

<b>Patient Name</b> SAMPLEREP, CVID	<b>Collection Date and Time</b> 05/08/2013 00:00	<b>Report Status</b> Final
Page 1 of 1	** End of Report **	

\* Report times for Mayo performed tests are CST/CDT